FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57203
News▼ Bearish
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 11:15 UTC
LAST UPDATE2026-09-30 11:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A bid-price compliance extension signals continued listing risk for the small-cap biotech.
Small-cap faces Nasdaq delisting pressure
CATALYST TO WATCH
Bid price recovery before deadline
MAIN RISK
Failure to regain compliance delists shares
FULL DISPATCH
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTNasdaq Composite · ^IXIC
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
Union, governor’s office strike deal on state employee healthcare costs2026-09-29 22:54 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
New Phase 3 trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy — Novartis2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.